 Five Prime Therapeutics Inc NASDAQ: FPRX shares are seeing astronomical gains Wednesday in reaction to a positive data readout. What Happened: Bemarituzumab, a targeted therapy, in combination with FOLFOX6 chemotherapy, met all three efficacy endpoints in the Phase 2 study dubbed FIGHT in patients with fibroblast growth factor receptor 2b-positive, non HER2 positive, front-line advanced gastric or gastroesophageal junction cancer, the South San Francisco, California-based company said, citing topline results. 